For US Healthcare Professionals
I am a:
HELP YOUR APPROPRIATE PATIENTS WITH MODERATE TO SEVERE PLAQUE PsO
Emerge
Tremfyant®
Co-primary endpoints (Week 16): PASI 90: 73% in VOYAGE 1 and 70% in VOYAGE 2; IGA 0/1: 85% in VOYAGE 1 and 84% in VOYAGE 2.1,2
IN ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS (PsO)
INTRODUCING THE
Clearance
Photo Library
The latest innovation in psoriasis imagery for TREMFYA® is here. Hundreds of real patient photos were collected to help visualize how psoriasis can present across a range of patients.
AFTER CONSIDERING THE EFFICACY AND SAFETY OF TREMFYA® FOR PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS (PsO)
Choose TREMFYA®.
Get TREMFYA®.
ONCE A DECISION HAS BEEN MADE TO PRESCRIBE TREMFYA®
Help your patients start and stay on TREMFYA® with the enhanced TREMFYA withMe program
The patient support and resources provided by TREMFYA withMe are not intended to give medical advice, replace a treatment from the patient’s healthcare provider, offer services that would normally be performed by the provider’s office, or serve as a reason to prescribe TREMFYA®.
AFTER CONSIDERING THE EFFICACY AND SAFETY OF TREMFYA® FOR PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS (PsO)
Access optionsfor all patients,
regardless of insurance coverage
Access options for allpatients, regardless of insurance coverage
Nearly 100%* commercial access
Clear
PsO
At Week 24, 53% of patients in VOYAGE 1 and 48% of patients in VOYAGE 2 achieved IGA 0. At Week 48, 47% of patients in VOYAGE 1 achieved IGA 0.1,2
Consistent
PsO
In VOYAGE 1, PASI 90 response rates were consistent between doses from Weeks 20-48.2,3
Durable
PsA
PsO
In open-label extensions, PASI 90 response rates were maintained from Week 52-252 in VOYAGE 1 and durable joint improvement was seen at Week 100 in DISCOVER 2 based on ACR50 response rates.2-4†
*These percentages may not represent 100% of formulary lives due to data limitations. Source: Managed Markets Insight and Technology, LLC™, a trademark of MMIT, as of May 2024.
†Patients who lose response or are unable to tolerate treatment are likely to discontinue treatment, which may increase the response rate in an as-observed analysis. The same patients may not have responded at each time point.
ACR50=50% improvement in American College of Rheumatology composite measures of arthritis; IGA=Investigator’s Global Assessment; PASI=Psoriasis Area and Severity Index.
NOW AVAILABLE
The Clearance
Explore hundreds of real patient photos of moderate to severe plaque psoriasis ranging in:
- disease severity
- areas of involvement
- all skin tones
ONCE A DECISION HAS BEEN
MADE TO PRESCRIBE TREMFYA®
ONCE A DECISION HAS BEEN MADE TO PRESCRIBE TREMFYA®
TREMFYA withMe provides a range of dedicated support and resources for patients throughout their TREMFYA® treatment journey.
The only IL-23 inhibitor with the One-Press patient-controlled injector
Optimized dosing5
The TREMFYA® 8-week dosing schedule was optimized in clinical trials1,5
Controlled delivery
Patients inject at a speed that is comfortable for them
Not actual size.
TREMFYA® is administered as a 100-mg subcutaneous injection once every 8 weeks, after starter doses at Weeks 0 and 4. TREMFYA® is intended for use under the guidance and supervision of a physician. Patients may self-inject with TREMFYA® after physician approval and proper training. In active PsA, TREMFYA® may be administered alone or in combination with a conventional DMARD (eg, methotrexate).
DMARD=disease-modifying antirheumatic drug.
References: 1. TREMFYA® (guselkumab) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 2. Blauvelt A, Papp KA, Griffiths CEM, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405-417. 3. Data on file. Janssen Biotech, Inc. 4. McInnes IB, Rahman P, Gottlieb AB, et al. Efficacy and safety of guselkumab, a monoclonal antibody specific to the p-19 subunit of interleukin-23, through two years: results from a phase III, randomized, double-blind, placebo-controlled study conducted in biologic-naïve patients with active psoriatic arthritis. Arthritis Rheumatol. 2022;74(3):475-485. 5. Lebwohl M, Langley RG, Zhu Y, et al. Use of dose-exposure-response relationships in Phase 2 and Phase 3 guselkumab studies to optimize dose selection in psoriasis.J Eur Acad Dermatol Venereol. 2019;33(11):2082-2086.
